Regeneron Pharmaceuticals REGN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Other products | $10.1M— | —— | $0— | —— | |
| (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net | -$69.6M-48.7% | -$46.8M+44.1% | -$83.7M— | —— | |
| Reimbursement For Manufacturing Of Commercial Supplies | $642.3M+5.7% | $607.9M-0.8% | $613M-3.3% | $633.7M+29.6% | |
| Reimbursement Of Commercialization Related Expenses | $729.3M+11.3% | $655.4M+22.6% | $534.4M+22.2% | $437.4M+36.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Regeneron Pharmaceuticals break its business down?
- Regeneron Pharmaceuticals (REGN) reports revenue by product across 5 parts — Lynozyfic, Other products, (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net, Reimbursement For Manufacturing Of Commercial Supplies and Reimbursement Of Commercialization Related Expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Regeneron Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regeneron Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
